Document is current

Article History

Received: 20 January 2025

Accepted: 23 April 2025

First Online: 7 May 2025

Declarations

:

: M.Ba. has received speaking and lecture fees from Amgen, Daichii Sankyo, Kogen, KRKA, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Sanofi-Aventis, Teva, and Zentiva, as well as consultation or advisory fees from Amgen, Daichii Sankyo, Esperion, NewAmsterdam, Novartis, Novo-Nordisk, Polfarmex, and Sanofi-Aventis. Additionally, he has received funding or grants from Amgen, Daichii Sankyo, Mylan/Viatris, and Sanofi, all unrelated to this work. G.B.-Z. has received consultation or advisory fees from Amarin, Balmed, Cardionovum, Crannmedical, Endocore Lab, Eukon, Guidotti, Innovheart, Meditrial, Microport, Opsens Medical, Terumo, and Translumina, all unrelated to this work. P.S. has received speaking and lecture fees from AstraZeneca, Amgen, Axis TV, BMS, Les Laboratoires Servier, Novartis, Novo Nordisk, Sanofi, and Vifor, all unrelated to this work. E.M. has received consultation or advisory fees from Pfizer, all unrelated to this work. All other authors have declared no conflicts of interest related to this work.

: Not applicable.

: Not applicable, as this is a review article with no original research involving humans or animals.